FDA Grants Breakthrough Therapy Designation for Tezepelumab for Severe Asthma
AstraZeneca and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers. Lesen Sie weiter auf: FDA Grants Breakthrough Therapy [...] .../Auszug
